Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000395 · ClinicalTrials.gov registry record · Phase 2

Antifolate Effectiveness in Arthritis

A Phase 2 study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target

NCT00000395 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000395, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by this vitamin because we think that blocking many of these reactions may be necessary for methotrexate to work in treating rheumatoid arthritis. Through these studies, we hope to gain a better understanding of how this drug and related drugs work as treatments for arthritis.

Interventions

  • DRUG Methotrexate
  • DIETARY_SUPPLEMENT Folic acid
  • DIETARY_SUPPLEMENT Folinic acid

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 1996-09
Est. Completion 2002-08
Phase Phase 2

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT00000395

The ClinicalTrials.gov registry entry for NCT00000395 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Methotrexate is the first listed.

NCT00000395 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00000395 about?

NCT00000395 is a clinical study titled "Antifolate Effectiveness in Arthritis". This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by th...

What is the current status of trial NCT00000395?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1996-09. Estimated completion is 2002-08.

What interventions are being tested in trial NCT00000395?

The interventions under investigation include: Methotrexate (DRUG), Folic acid (DIETARY_SUPPLEMENT), Folinic acid (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00000395?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.